Introduction
============

It was reported that mid-wall striate late gadolinium enhancement at interventricular septum (MWS-LGE) definite by CMR was strong predictor of prognosis including sudden death with dilated cardiomyopathy (DCM). On the other hand, randomized trial have shown that beta-brokers lead symptomatic improvement, reduced hospitalization and enhanced survival in many patients with heart failure.

Purpose
=======

The object of this study was to evaluate the impact of mid-wall striate of LGE(MWS-LGE) at interventricular septum to beta-broker (Carvedilol) titrating to the target dose and improvement of cardiac function with DCM.

Methods
=======

Fifty-five patients with DCM examined by LGE-CMR were enrolled. They were treated with Carvedilol at higher dose as possible.

They were divided into two groups according to MWS-LGE positive or not.

The maximum dose of Carvedilol with each group at chronic stable condition(after 21.6 +/- 21.4 months later from initiation of Carvedilol) were compared. The improvement of UCG parameter of each group by Carvedilol therapy was examined.

Results
=======

1\) The UCG parameters of all 55 DCM patients recorded just before initiation of Carvedilol were LVDd; 65.2±7.5mm,LVDs; 56.3±8.5mm,EF;28.2.±8.1% and mean final dose of Carvedilol with all 55 DCM patients was 11.5±5.5mg.

2\) MWS-LGE was found in twenty patients of DCM (38.1%) with LGE-CMR.

3\) There were no significant difference between two groups in LVDd, LVDs and EF(P\>0.79,P\>0.92,P\>0.76, respectively)at first echocardiograph.

4\) The final dose of carvedilol with MWS-LGE -positive group was lower than with MWS-LGE -negative group (9.2+/-5.4 mg VS 13.0 +/-5.1mg, respectively).

5\) The UCG parameter showed improvement at chronic stable phase compared to those had recorded at just before initiation of Carvedilol in the both groups, but especially in the MWS-LGE negative group showed a greater improvement than those of MWS-LGE positive group (Table [1](#T1){ref-type="table"}).

###### 

The UCG parameters at chronic stable phase

  MWS-LGE    LVDd(mm)      LVDs(mm)      EF(%)
  ---------- ------------- ------------- -------------
  Negative   54.4+/-7.7    39.8+/-9.9    52.3+/-14.2
  Positive   63.1+/-10.9   52.4+/-14.8   36.2+/-18.1
  P-value    \<0.02        \<0.02        \<0.01

Conclusions
===========

The relationship between the beneficial effect of Carvedilol with DCM and MWS-LGE defined by LGE-MRI was examined. The DCM patients with MWS-LGE negative showed higher maximum dose of Carvedilol and greater improvement of UCG parameters compared to those of patients with MWS-LGE positive. The MWS-LGE has a potential to have a strong worse impact to titrating and beneficial effect of Carvedilol with DCM.
